Search results
Results from the WOW.Com Content Network
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
Moderna Inc (NASDAQ: MRNA) reported mixed quarterly results Thursday and suggested an interim efficacy readout from the Phase 3 study is likely in November.The Moderna Bull Case: Moderna's vaccine ...
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...
Investors will likely focus on the progress of Moderna's (MRNA) late-stage pipeline candidates during the third-quarter earnings call, which can lower its dependence on COVID vaccine sales.
As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural for investors to wonder about where the biotech will go in the near ...
The S&P 500 closed lower on Tuesday, as investors focused on a report questioning Moderna's recent coronavirus vaccine early-stage trial results, wiping out modest gains on the benchmark index in ...